ICYMI: Policy Experts Call Out Big Pharma for Setting Exorbitant List Prices:

University of Chicago Professor of Economics and current Chief Counsel for Advocacy at the Small Business Administration, Casey Mulligan, developed an economic model to estimate the overall value that PBMs provide to the American health care system. Dr. Mulligan’s research,

"When you're hit from all sides — by natural disasters, inflation and rising health care costs — you pay attention when someone promises relief. That's why proposals to lower drug prices are grabbing policymakers attention in places like Louisiana, where the damage of annual

PCMA issued the following statement on the Trump Administration’s actions today to outline the steps that drug companies must take to lower the prices of prescription drugs for Americans:

PBMs recognize the critical value of pharmacists in our communities and that, especially in rural areas, patients may depend on their pharmacist for more than filling prescriptions.

Patent abuse is anticompetitive, drives up health care costs, and limits access to prescription drugs for patients who need them. Increased competition in the prescription drug marketplace is a proven path to lower drug costs, and this bill would be a step in the right direction

Up to half of patients may not be following their medication regimens due to factors like fear of side effects, misunderstanding the need for the drug and cost-sharing challenges set by #BigPharma. See how #PBMs are innovating to help patients better adhere to their Rx drugs:

PBMs help the entire health care system by driving down prescription drug costs, saving money for patients and health plan sponsors. Learn more:

Up to half of patients may not be following their medication regimens due to factors like fear of side effects, misunderstanding the need for the drug, and cost-sharing challenges set by Big Pharma. See how PBMs are innovating to help patients better adhere to their Rx drugs:

PBMs have repeatedly called on drug companies to lower list prices on their products to benefit consumers, including on specific drug classes, like high-priced GLP-1 treatments for weight loss. The ball is in Big Pharma’s court to lower prices. Learn more:

Every year, like clockwork, drug prices go up. For many patients, those increases aren’t just numbers on a chart; they’re real barriers to getting the care they need. That’s where PBMs come in, helping to mitigate the financial pressures and barriers to access that come with high

"Rising healthcare costs are primarily driven by manufacturer monopolies, FDA-induced supply bottlenecks, and anti-competitive patent gamesmanship, all of which pharmaceutical companies have exploited to their sole financial benefit, while painting PBMs as villains."

No employer or plan sponsor is required to use #PBMs – they choose to do so because of the valuable services they provide in lowering #RxDrug costs for them and their plan enrollees.

"Banning PBMs would hit veterans and rural residents hard. Here's why."

Johnny Garcia, PharmD, and PCMA's AVP of Policy, explains how nonadherence impacts health and the many ways that PBMs are innovating to promote medication adherence for patients. Learn more about how PBMs innovate.

PCMA wishes everyone a safe and fun 4th of July.

PCMA released the following statement on the United States Supreme Court’s decision to decline review of the 2023 ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready. The decision by the high court solidifies PCMA’s successful challenge to four

PCMA issued the following statement on the Restore Prescription Drugs Discount Act, introduced by U.S. Senator Rand Paul (R-KY)

"Don’t let bad policy fuel healthcare inflation."

"We’d pay even more if private health plans didn’t pool patients together and collectively bargain on drug prices through intermediary Pharmacy Benefit Managers (PBMs)."